Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases insulin synthesis and decreases glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/gastrointestinal tract, not the renal system.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
5 mg orally once daily. Can be taken with or without food.
## Pediatric Dosing
Safety and efficacy in pediatric patients (under 18 years) have not been established. Use is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis.
## Adverse Effects
* **Common:** Nasopharyngitis.
* **Serious:** Acute pancreatitis (including fatal cases), severe and disabling arthralgia, blistering skin conditions (bullous pemphigoid), and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers:** Rifampin may decrease linagliptin efficacy; monitor glycemic control closely if co-administration is necessary.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia when used in combination; consider dose reduction of the secretagogue or insulin.
## Monitoring
* **Glycemic Control:** HbA1c (goal typically <7%) and self-monitoring of blood glucose.
* **Pancreatitis:** Monitor for signs of severe, persistent abdominal pain radiating to the back.
* **Skin:** Monitor for development of blisters or erosions.
## Clinical Pearls
* **Renal Utility:** Linagliptin is a preferred DPP-4 inhibitor for patients with stage 4 or 5 chronic kidney disease because it does not require renal dose adjustment.
* **No Weight Gain:** It is considered weight-neutral.
* **No Hypoglycemia:** When used as monotherapy, the risk of hypoglycemia is low.
* **Administration:** Swallow the tablet whole; do not split or crush.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always verify specific dosing, safety warnings, and contraindications via official manufacturer labeling (e.g., FDA-approved package insert) or institutional clinical protocols before prescribing or administering medication.
